ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 440

Disease Activity and Quality of Life in Behçet’s Syndrome: The Role of Patient Reported Outcome

Antonio Figliomeni1, Alice Parma 1, Viola Signorini 2, Emanuele Calabresi 1, Rosaria Talarico 1 and Marta Mosca 3, 1Università di Pisa, PISA, Italy, 2Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Toscana, Italy, 3Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: and quality of life, Behcet's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Behçet’s syndrome (BS) is a systemic vasculitis, characterised by recurrent oro-genital ulcers, ocular inflammation and skin manifestations; articular, vascular, gastro-enteric and neurological involvement may also occur.The complex pattern of BS profile can effect negatively on patients’ quality of life.
The primary aim of this study was to explore the role of quality of life in BS patients by means of patient reported outcome (PRO); the secondary aim was to study any correlation between disease activity, psychiatric symptoms and quality of life.

Methods: The study enrolled 147 patients (86 M, 61 F), all fulfilling the International Study Group (ISG) criteria for BS. Their mean age was 41 ± 7 years (18-77), while the disease duration was 11 ± 4 years (5-18) and the mean follow-up of 7 ± 3 years.
Disease activity was evaluated by means of the Behçet’s Disease Current Activity Form (BDCAF), while Short-form-36 (SF-36) was used to evaluate quality of life. Disease activity was compared with the global SF-36 score and with each dimension, that includes physical functioning, physical disability, body pain, general health, vitality, social functioning, emotional disability, mental health according the Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-IV). The statistical analysis was performed using Student t-test, Mann-Whitney-U test, ANOVA, and Pearson correlation.

Results: At time of evaluation, according BDCAF, 48 BS patients (33%) had clinically active disease characterized by concomitant types of involvement (40 muco-cutaneous involvement, 18 ocular involvement 8 joint involvement, 5 neurological involvement, 4 gastro-enteric). As expected, the overall SF- 36 scores were significantly lower in patients with clinically active disease. Notably, female BS patients had statistically significant lower scores in all SF-36 domains compared with male patients. When each domain of SF-36 was evaluated, we found that physical disability (p=0.004), body pain (p=0.006), general health (p=0.001), and vitality (p=0.001) were significantly lower in patients with disease activity. Notably, vitality (p=0.001), physical disability(p=0.004), social functioning (p=0.001), emotional disability (p=0.003) and mental health (p=0.001) were significantly lower in patients with muco-cutaneous active disease, compared with the other patients with active disease. Moreover, we found a significant correlation between disease activity, high frequency of bipolar disorder and worsening of quality of life.

Conclusion: The combination of PRO measures and disease activity have been demonstrated to add more information compared to the evaluation of disease activity alone. These considerations suggest that the correct assessment of BS needs a multi-dimensional approach, that includes disease activity, disease damage and quality of life.


Disclosure: A. Figliomeni, None; A. Parma, None; V. Signorini, None; E. Calabresi, None; R. Talarico, None; M. Mosca, None.

To cite this abstract in AMA style:

Figliomeni A, Parma A, Signorini V, Calabresi E, Talarico R, Mosca M. Disease Activity and Quality of Life in Behçet’s Syndrome: The Role of Patient Reported Outcome [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/disease-activity-and-quality-of-life-in-behc%cc%a7ets-syndrome-the-role-of-patient-reported-outcome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-and-quality-of-life-in-behc%cc%a7ets-syndrome-the-role-of-patient-reported-outcome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology